[HTML][HTML] QGP-1 cells release 5-HT via TRPA1 activation; a model of human enterochromaffin cells
H Doihara, K Nozawa, R Kojima… - Molecular and cellular …, 2009 - Springer
Recently, we discovered that transient receptor potential ankyrin1 channel (TRPA1) is highly
expressed in human and rat enterochromaffin (EC) cells, and those TRPA1 agonists such as …
expressed in human and rat enterochromaffin (EC) cells, and those TRPA1 agonists such as …
Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment
A Walenkamp, G Crespo, FF Maya… - Endocrine-related …, 2014 - erc.bioscientifica.com
In the past few years, there have been advances in the treatment of neuroendocrine tumours
(NETs) and improvements in our understanding of NET biology. However, the benefits to …
(NETs) and improvements in our understanding of NET biology. However, the benefits to …
Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy
F Viol, B Sipos, M Fahl, TS Clauditz, T Amin, M Kriegs… - Cellular Oncology, 2022 - Springer
Purpose Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) form a rare and
remarkably heterogeneous group of tumors. Therefore, establishing personalized therapies …
remarkably heterogeneous group of tumors. Therefore, establishing personalized therapies …
Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling
Background Between 10% and 20% of patients with neuroendocrine tumors (NETs) present
with metastases of unknown primary site. Because knowledge of the primary site has …
with metastases of unknown primary site. Because knowledge of the primary site has …
[HTML][HTML] Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines …
V Corbo, S Beghelli, S Bersani, D Antonello… - Annals of …, 2012 - Elsevier
Background Kinases represent potential therapeutic targets in pancreatic endocrine tumours
(PETs). Patients and methods Thirty-five kinase genes were sequenced in 36 primary PETs …
(PETs). Patients and methods Thirty-five kinase genes were sequenced in 36 primary PETs …
Endocrine tumours of the pancreas
CS Verbeke - Histopathology, 2010 - Wiley Online Library
Verbeke CS (2010) Histopathology 56, 669–682 Endocrine tumours of the pancreas
Histopathology reporting of pancreatic endocrine neoplasms is complex. The tumours can …
Histopathology reporting of pancreatic endocrine neoplasms is complex. The tumours can …
Neuroendocrine tumors show altered expression of chondroitin sulfate, glypican 1, glypican 5, and syndecan 2 depending on their differentiation grade
Neuroendocrine tumors (NETs) are found throughout the body and are important as they
give rise to distinct clinical syndromes. Glycosaminoglycans, in proteoglycan (PG) form or as …
give rise to distinct clinical syndromes. Glycosaminoglycans, in proteoglycan (PG) form or as …
Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells
A Di Florio, G Capurso, M Milione… - Endocrine-Related …, 2007 - erc.bioscientifica.com
Pancreatic endocrine tumours (PETs) are rare and 'indolent'neoplasms that usually develop
metastatic lesions and exhibit poor response to standard medical treatments. Few studies …
metastatic lesions and exhibit poor response to standard medical treatments. Few studies …
Gastroenteropancreatic endocrine tumors
A Meeker, C Heaphy - Molecular and cellular endocrinology, 2014 - Elsevier
Gastroenteropancreatic endocrine tumors (GEP-NETs) are relatively uncommon; comprising
approximately 0.5% of all human cancers. Although they often exhibit relatively indolent …
approximately 0.5% of all human cancers. Although they often exhibit relatively indolent …
Emerging kinase therapeutic targets in pancreatic ductal adenocarcinoma and pancreatic cancer desmoplasia
Kinase drug discovery represents an active area of therapeutic research, with previous
pharmaceutical success improving patient outcomes across a wide variety of human …
pharmaceutical success improving patient outcomes across a wide variety of human …